These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 25263322)
1. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Taylor M; Friedberg JW; Koff JL; Link BK; Cerhan JR; Dawson KL; Flowers CR Leuk Lymphoma; 2015 May; 56(5):1295-302. PubMed ID: 25263322 [TBL] [Abstract][Full Text] [Related]
2. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677 [TBL] [Abstract][Full Text] [Related]
4. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110 [TBL] [Abstract][Full Text] [Related]
5. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model. Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772 [TBL] [Abstract][Full Text] [Related]
6. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127 [TBL] [Abstract][Full Text] [Related]
7. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Casulo C; Byrtek M; Dawson KL; Zhou X; Farber CM; Flowers CR; Hainsworth JD; Maurer MJ; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW J Clin Oncol; 2015 Aug; 33(23):2516-22. PubMed ID: 26124482 [TBL] [Abstract][Full Text] [Related]
8. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial. Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K; Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034 [TBL] [Abstract][Full Text] [Related]
9. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era. Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937 [TBL] [Abstract][Full Text] [Related]
10. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969 [TBL] [Abstract][Full Text] [Related]
11. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266 [TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G; Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345 [TBL] [Abstract][Full Text] [Related]
13. New treatment options have changed the survival of patients with follicular lymphoma. Fisher RI; LeBlanc M; Press OW; Maloney DG; Unger JM; Miller TP J Clin Oncol; 2005 Nov; 23(33):8447-52. PubMed ID: 16230674 [TBL] [Abstract][Full Text] [Related]
14. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Nastoupil LJ; Sinha R; Byrtek M; Zhou X; Taylor MD; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR Cancer; 2014 Jun; 120(12):1830-7. PubMed ID: 24668580 [TBL] [Abstract][Full Text] [Related]
15. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. Dundar Y; Bagust A; Hounsome J; McLeod C; Boland A; Davis H; Walley T; Dickson R Health Technol Assess; 2009 Jun; 13 Suppl 1():23-8. PubMed ID: 19567210 [TBL] [Abstract][Full Text] [Related]
16. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Marcus R; Imrie K; Belch A; Cunningham D; Flores E; Catalano J; Solal-Celigny P; Offner F; Walewski J; Raposo J; Jack A; Smith P Blood; 2005 Feb; 105(4):1417-23. PubMed ID: 15494430 [TBL] [Abstract][Full Text] [Related]
17. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303 [TBL] [Abstract][Full Text] [Related]
18. Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. Kim HK; Kang W; Sinn DH; Lee JH; Kim WS; Kim SJ Korean J Intern Med; 2020 Jan; 35(1):194-204. PubMed ID: 30935195 [TBL] [Abstract][Full Text] [Related]